R
Ripple Therapeutics
Ripple Therapeutics : Highly Engineerable Drug Delivery Platform
About Ripple Therapeutics
Ripple Therapeutics is a clinical-stage company specializing in the development of advanced drug delivery systems for ophthalmic therapeutics. Utilizing its proprietary Epidel technology, Ripple Therapeutics engineers drugs into controlled release pharmaceuticals and medical device coatings without the need for polymers or excipients. This technology allows for the creation of implantable forms such as cylinders and microspheres, which deliver drugs in a highly predictable manner based on surface erosion. The company operates in the pharmaceutical and medical device markets, focusing on clients in the ophthalmology sector. Ripple Therapeutics generates revenue through licensing deals, such as their agreement with Laboratoires for North America and Europe, and aims to achieve commercial success through innovative product development and strategic partnerships. The company is led by a seasoned leadership team experienced in managing both small and large public and private companies through various stages of growth and financing strategies, including venture capital, M&A transactions, IPOs, and PIPEs. Ripple Therapeutics also invests in the future by providing meaningful work experiences for university students through co-operative education programs.
Source: Dealroom company dataAt a glance
- Founded
- 2019
- Headquarters
- Toronto, Canada
- Sector
- Biotech & Life Sciences
News
Open roles
Ripple Therapeutics in the Toronto ecosystem
The Ripple Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
- CFCovington Funds
MaRS Investment Accelerator Fund
DSM Firmenich
National Research Council Canada
Series A1 investor entered at this stage
Théa Open Innovation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ripple Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ripple Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


